

VALBIOTIS SIGNS TWO PARTNERSHIP AGREEMENTS, ONE WITH BIOFORTIS AND THE OTHER WITH THE UNIVERSITÉ CATHOLIQUE DE LOUVAIN AND PROFESSOR PATRICE D. CANI, TO ASSESS THE EFFECTS OF TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA[®], ON INTESTINAL MICROBIOTA

VALBIOTIS, a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, has announced today the signing of two partnership agreements, one with Biofortis (Merieux NutriSciences), and the other with the Université Catholique de Louvain (Belgium) and Prof. Patrice D. Cani¹ (PhD) as part of a program aimed at evaluating the efficacy of TOTUM-63, the active ingredient of Valedia[®], on intestinal microbiota.

Biofortis is a global research organization run by Mérieux NutriSciences with a focus on innovation in the food, nutrition, health, cosmetics and consumer goods sectors². Prof. Patrice Cani, a renowned international science expert, discovered in particular the beneficial role *Akkermansia muciniphila* plays on obesity and on cardiometabolic risk factors. This discovery was the focus of an article published in *Nature Medicine* in 2017³. Prof. Cani co-supervises the Metabolism and Nutrition Research Group at the Louvain Drug Research Institute (LDRI) of the Université Catholique de Louvain in Brussels.

Microbiota is found in every individual and refers to a community of microorganisms (bacteria, parasites, viruses and non-pathogenic fungi) living in a specific environment. The intestinal microbiota is the largest in the body and plays a key role in digestion, metabolic, immunological and neurological processes and, more recently discovered, in cardiological functions. A large amount of data now suggests that the microbiota possibly plays a major role in the evolution of type 2 diabetes and obesity.

TOTUM-63, the active ingredient of Valedia[®], is a synergistic combination of 5 plant extracts developed by VALBIOTIS that has already proven its ability to regulate several pre-diabetes risk factors in preclinical studies and in Phase I/II clinical study. This new program in collaboration with Biofortis, the Université Catholique de Louvain and Prof. Patrice D. Cani, would help validate the effects of TOTUM-63 on the microbiota and on the microbiome, its environment.

Based on the synergy of expertise, this collaborative partnership will include several in-depth preclinical and clinical analysis, with the aim of announcing the results in the first quarter of 2018. Biofortis and Prof. Cani will analyze the samples collected during the preclinical studies as well as the human biological samples collected by VALBIOTIS.

¹ Member of the Valbiotis Scientific and Medical Committee

² More information on: <http://www.merieuxnutrisciences.fr/fr/fra/notre-offre/biofortis-innovation-services>

³ Source: <http://www.nature.com/nm/journal/v23/n1/full/nm.4236.html>

ABOUT VALBIOTIS

VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic disease and provide nutritional support for patients. Its products are made for manufacturers in the agro-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular disease.

Valbiotis was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. Valbiotis is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

For more information about VALBIOTIS:

<http://valbiotis.com/>



CONTACTS

VALBIOTIS
Sébastien Peltier, CEO

PRESS RELATIONS
ALIZE RP
Caroline Carmagnol / Wendy Rigal / Laetitia Abbar
+33 1 44 54 36 66
valbiotis@alizerp.com